Compared with enteral nutrition (EN), patients treated with parenteral nutrition (PN) are more likely to have significant hyperglycemia because PN bypasses glucagon-like peptide-1 and gastric inhibitory polypeptide in the gastrointestinal tract, resulting in the loss of the incretin effect (36). Here, GIP is linked to Hyperglycemia.